Parvoduk
live attenuated Muscovy duck parvovirus
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for Parvoduk has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.
This EPAR was last updated on 15/04/2019
Authorisation details
| Product details | |
|---|---|
| Name |
Parvoduk
|
| Agency product number |
EMEA/V/C/002740
|
| Active substance |
live attenuated Muscovy duck parvovirus
|
| International non-proprietary name (INN) or common name |
live attenuated Muscovy duck parvovirus
|
| Species |
Ducks
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI01BD03
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Merial
|
| Revision |
2
|
| Date of issue of marketing authorisation valid throughout the European Union |
11/04/2014
|
| Contact address |
29 Avenue Tony Garnier |
Product information
09/01/2019 Parvoduk - EMEA/V/C/002740 - R/0006
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
-
duck parvovirus
-
Live viral vaccines
-
Immunologicals for aves
Therapeutic indication
Therapeutic indication
Active immunisation of ducks to prevent mortality1 and to reduce weight loss and lesions of duck parvovirosis and Derzsy's disease.
1In absence of maternally derived antibodies.